CN102741249B - 杂芳基-[1,8]萘啶衍生物 - Google Patents

杂芳基-[1,8]萘啶衍生物 Download PDF

Info

Publication number
CN102741249B
CN102741249B CN201080063064.6A CN201080063064A CN102741249B CN 102741249 B CN102741249 B CN 102741249B CN 201080063064 A CN201080063064 A CN 201080063064A CN 102741249 B CN102741249 B CN 102741249B
Authority
CN
China
Prior art keywords
cyy
compound
atoms
phenyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080063064.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102741249A (zh
Inventor
A·约恩齐克
D·多施
G·赫尔策曼
C·阿门特
F·岑克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN102741249A publication Critical patent/CN102741249A/zh
Application granted granted Critical
Publication of CN102741249B publication Critical patent/CN102741249B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201080063064.6A 2010-02-05 2010-12-17 杂芳基-[1,8]萘啶衍生物 Expired - Fee Related CN102741249B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10001251.7 2010-02-05
EP10001251 2010-02-05
PCT/EP2010/007743 WO2011095196A1 (en) 2010-02-05 2010-12-17 Hetaryl-[1,8]naphthyridine derivatives

Publications (2)

Publication Number Publication Date
CN102741249A CN102741249A (zh) 2012-10-17
CN102741249B true CN102741249B (zh) 2015-11-25

Family

ID=43531801

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080063064.6A Expired - Fee Related CN102741249B (zh) 2010-02-05 2010-12-17 杂芳基-[1,8]萘啶衍生物

Country Status (14)

Country Link
US (2) US8614226B2 (OSRAM)
EP (1) EP2531500B1 (OSRAM)
JP (1) JP5675850B2 (OSRAM)
KR (1) KR20120124469A (OSRAM)
CN (1) CN102741249B (OSRAM)
AU (1) AU2010344973B2 (OSRAM)
BR (1) BR112012018954A2 (OSRAM)
CA (1) CA2789021C (OSRAM)
EA (1) EA201201081A1 (OSRAM)
ES (1) ES2667049T3 (OSRAM)
MX (1) MX2012008550A (OSRAM)
SG (1) SG182803A1 (OSRAM)
WO (1) WO2011095196A1 (OSRAM)
ZA (1) ZA201206630B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183233A1 (en) * 2010-02-22 2012-09-27 Merck Patent Gmbh Hetarylaminonaphthyridines
AU2011273931B2 (en) * 2010-06-28 2015-04-23 Merck Patent Gmbh 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer
JP6418738B2 (ja) * 2010-07-07 2018-11-07 ダウ アグロサイエンシィズ エルエルシー 官能化直鎖ｄｎａカセットの製造および植物における量子ドット／ナノ粒子媒介送達
KR20130118612A (ko) * 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
JP6496246B2 (ja) 2012-10-05 2019-04-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アルドステロンシンターゼインヒビター関連用途としてのインドリン化合物
CN104837832B (zh) * 2012-10-05 2019-04-26 里格尔药品股份有限公司 Gdf-8抑制剂
EP2948447B1 (en) 2013-01-23 2016-09-21 Astrazeneca AB Chemical compounds
CN103113369A (zh) * 2013-03-21 2013-05-22 云南大学 一种具有抗肿瘤活性的苯并[b][1,8]-萘啶-2-(1H)-亚胺衍生物及合成方法
TWI529171B (zh) * 2013-07-29 2016-04-11 赫孚孟拉羅股份公司 １，７－萘啶衍生物
US10233176B2 (en) 2013-11-27 2019-03-19 Signalchem Lifesciences Corporation Aminopyridine derivatives as TAM family kinase inhibitors
US10202373B2 (en) 2014-01-14 2019-02-12 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
MX2016009135A (es) * 2014-01-14 2016-10-05 Millennium Pharm Inc Heteroarilos y usos de estos.
ES2759240T3 (es) * 2014-04-08 2020-05-08 Rigel Pharmaceuticals Inc Compuestos de piridina 2,3-disustituidos como inhibidores de TGF-beta
CN112074505B (zh) 2018-03-08 2024-04-05 因赛特公司 作为PI3K-γ抑制剂的氨基吡嗪二醇化合物
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
EP4087657A1 (en) 2020-01-08 2022-11-16 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
WO2024258967A1 (en) 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453423A (en) * 1991-04-09 1995-09-26 Boehringer Mannheim Italia S.P.A. Heterocyclic amines useful in the therapy of asthma and imflammation of the respiratory tract
CN1259947A (zh) * 1997-03-07 2000-07-12 北卡罗来纳-查佩尔山大学 作为抗肿瘤药的2－芳基－萘啶－4－酮类
US20040072823A1 (en) * 1997-10-27 2004-04-15 Neurosearch A/S Heteroaryl diazacycloalkanes, their preparation and use;
WO2004081009A1 (en) * 2003-03-12 2004-09-23 Millennium Pharmaceuticals, Inc. Quinazoline derivatives as tgf-beta inhibitors
EP1724268A1 (en) * 2004-02-20 2006-11-22 Kirin Beer Kabushiki Kaisha Compound having tgf-beta inhibitory activity and pharmaceutical composition containing same
EP1849773A1 (en) * 2005-02-17 2007-10-31 Astellas Pharma Inc. Pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivative
US20090181941A1 (en) * 2008-01-11 2009-07-16 Catherine Leblanc Pyrrolopyrimidines and Pyrrolopyridines

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR207555A1 (es) 1972-12-04 1976-10-15 Procedimiento para preparar aril-6-piperazinocarboniloxi-5 oxo-7 tetrahidro-2,3,6,7 ditiino(1,4)(2,3-c)pirroles
AU4972900A (en) 1999-04-08 2000-11-14 Arch Development Corporation Use of anti-vegf antibody to enhance radiation in cancer therapy
GB0117060D0 (en) * 2001-07-12 2001-09-05 Merck Sharp & Dohme Therapeutic agents
US20040038856A1 (en) * 2002-05-17 2004-02-26 Sarvajit Chakravarty Treatment of fibroproliferative disorders using TGF-beta inhibitors
BRPI0619424B1 (pt) 2005-12-05 2022-02-08 Pfizer Products Inc Uso de inibidores c-met/hgfrs para a fabricação de medicamentos
JP4751856B2 (ja) 2007-07-03 2011-08-17 本田技研工業株式会社 車体側部構造
DE102007049451A1 (de) 2007-10-16 2009-04-23 Merck Patent Gmbh 5-Cyano-thienopyridine
JP2011511005A (ja) 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド ２−アミノピリジン系キナーゼ阻害薬
DE102008017853A1 (de) 2008-04-09 2009-10-15 Merck Patent Gmbh Thienopyrimidine
EA201001687A1 (ru) 2008-04-29 2011-06-30 Новартис Аг Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 )
AU2010265971B2 (en) * 2009-06-25 2014-08-14 Amgen Inc. Heterocyclic compounds and their uses as inhibitors of PI3 K activity
SG183233A1 (en) * 2010-02-22 2012-09-27 Merck Patent Gmbh Hetarylaminonaphthyridines
AU2011273931B2 (en) * 2010-06-28 2015-04-23 Merck Patent Gmbh 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453423A (en) * 1991-04-09 1995-09-26 Boehringer Mannheim Italia S.P.A. Heterocyclic amines useful in the therapy of asthma and imflammation of the respiratory tract
CN1259947A (zh) * 1997-03-07 2000-07-12 北卡罗来纳-查佩尔山大学 作为抗肿瘤药的2－芳基－萘啶－4－酮类
US20040072823A1 (en) * 1997-10-27 2004-04-15 Neurosearch A/S Heteroaryl diazacycloalkanes, their preparation and use;
WO2004081009A1 (en) * 2003-03-12 2004-09-23 Millennium Pharmaceuticals, Inc. Quinazoline derivatives as tgf-beta inhibitors
EP1724268A1 (en) * 2004-02-20 2006-11-22 Kirin Beer Kabushiki Kaisha Compound having tgf-beta inhibitory activity and pharmaceutical composition containing same
EP1849773A1 (en) * 2005-02-17 2007-10-31 Astellas Pharma Inc. Pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivative
US20090181941A1 (en) * 2008-01-11 2009-07-16 Catherine Leblanc Pyrrolopyrimidines and Pyrrolopyridines

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A Novel Class of Highly Potent and Selective A1 Adenosine Antagonists:Structure-Affinity Profile of a Series of 1,8-Naphthyridine Derivatives;Pier Luigi Ferrarini 等;《Journal of Medicinal Chemistry》;20000708;第43卷(第15期);第2814-2823页 *
A Novel Synthesis and Potent Antiinflammatory Activity of 4-Hydroxy-2(1H)-oxo-1-phenyl-1,8-naphthyridine-3-carboxamides;Takeshi Kuroda 等;《J. Med. Chem.》;19921231;第35卷(第6期);第1132页流程图IV化合物13 *
Antitumor Agents. 199. Three-Dimensional Quantitative Structure-Activity Relationship Study of the Colchicine Binding Site Ligands Using Comparative Molecular Field Analysis;Shun-Xiang Zhang 等;《Journal of Medicinal Chemistry》;20000106;第43卷(第2期);第168页表1中化合物36和38 *
Facile One-Pot Synthesis of N-Difluoromethyl-2-pyridone Derivatives;Makoto Ando 等;《ORGANIC LETTERS》;20060718;第8卷(第17期);第3807页表格2中化合物10 *
Synthesis and 3D QSAR of New Pyrazolo[3,4-b]pyridines: Potent and Selective Inhibitors of A1 Adenosine Receptors;Fabrizio Manetti 等;《Journal of Medicinal Chemistry》;20051015;第48卷(第23期);第7172-7185页 *
Über eine Synthese von Derivaten des 1,8-Naphthyridins;Georg Koller;《Chemische Berichte》;19271231;第60卷(第2期);第408页化合物I、II、III *

Also Published As

Publication number Publication date
AU2010344973A1 (en) 2012-09-20
EP2531500B1 (en) 2018-01-24
WO2011095196A1 (en) 2011-08-11
JP5675850B2 (ja) 2015-02-25
ES2667049T3 (es) 2018-05-09
US8614226B2 (en) 2013-12-24
EP2531500A1 (en) 2012-12-12
BR112012018954A2 (pt) 2016-04-12
US20140038960A1 (en) 2014-02-06
ZA201206630B (en) 2013-05-29
KR20120124469A (ko) 2012-11-13
CA2789021A1 (en) 2011-08-11
JP2013518832A (ja) 2013-05-23
EA201201081A1 (ru) 2013-03-29
SG182803A1 (en) 2012-09-27
US20120295902A1 (en) 2012-11-22
US8912216B2 (en) 2014-12-16
AU2010344973B2 (en) 2016-06-16
CN102741249A (zh) 2012-10-17
MX2012008550A (es) 2012-09-07
CA2789021C (en) 2018-02-06

Similar Documents

Publication Publication Date Title
CN102741249B (zh) 杂芳基-[1,8]萘啶衍生物
CN103097381B (zh) 作为激酶抑制剂的1,8-萘啶物质
JP7075399B2 (ja) Ｒｅｔキナーゼ阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物
KR102212923B1 (ko) 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
CN102958930B (zh) 作为用于对抗癌症的激酶抑制剂的2,4-二芳基取代的[1,8]二氮杂萘化合物
JP5886842B2 (ja) キナーゼ誘発疾患の処置に有用なビピリジル誘導体
JP2022525199A (ja) Ｅｅｄおよびｐｒｃ２調節物質としての大環状アゾロピリジン誘導体
HK1177209A (en) Hetaryl-[1,8]naphthyridine derivatives
HK1185067A (en) Hetarylaminonaphthyridines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1177209

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151125